Printer Friendly

COMPANY INFORMATION
OccuLogix, Inc. Unit 9, 103-2600 Skymark Dr Mississauga, ON L4W 5B2 Tel: (905) 602-0887 Toll-free: (866) 622-8564 Fax: (905) 602-7623 Contact Name Stephen J. Kilmer Industry Biotechnology		Key Executives Elias Vamvakas, CEO William G. Dumencu, CFO Develops technologies which enables eye care practitioners to test, at the point-of-care, for highly sensitive and specific biomarkers using nanoliters of tear film.
FP ADVISOR COVERAGE OccuLogix, Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 5/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/TLB Nasdaq/TEAR $1.13 $3.75 $1.11 n.a. n.a. n.a. 1.3 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 801 1.90 US$0.54 Sept. 30/09 -53.92% -72.24% -66.99% $11,149
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08A 12m Dec. 31/07A 12m Dec. 31/06A US$000s US$000s US$000s Operating revenue 458 92 206 Net income (9,368) (69,830) (82,279) Total assets 13,405 15,313 90,404 US$ US$ US$ Earnings per share* (2.29) (30.75) (45.75) % % % Return on equity (206.89) (105.49) (87.88)   * Common A Reported in accordance with U.S. GAAP
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09A Sept. 30/08A US$000s US$000s Operating revenue 903 24 Net income (4,950) (48,724) US$ US$ Earnings per share (0.51) (21.25)   A Reported in accordance with U.S. GAAP

COMPANY NEWS

Results for 'OccuLogix, Inc.' from past 30 days: No hits. (Links are to articles.)